Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Lip and Oral Cavity Cancer Therapeutics – Pipeline Assessment and Market Forecasts to 2018The Lip and Oral Cavity Cancer Therapeutics Market is Forecast to Show Steady Growth until 2018
By: Rajesh Gunnam Spain and Japan) lip and oral cavity cancer therapeutics market was worth $114.79m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 2.7% to reach $142.52m by 2018. The existing market is strong, and is represented by two approved products, Erbitux and Taxotere, of which only the former is patent protected. Erbitux is currently approved in the US and European Union (EU) but not in Japan. The growth during 2005-2010 is primarily attributed to the launch of Taxotere and Erbitux for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN). The steady growth rate during the forecast period is attributed to the increasing prevalence of lip and oral cavity cancer, which has led to an increase in the drug-treated population. The expected launch of Multikine towards the latter part of the forecast period (2017 in the US and the EU) for the treatment of advanced primary SCCHN is expected to further contribute towards the growth of the lip and oral cavity cancer therapeutics market. GlobalData has found that the lip and oral cavity cancer market has significant unmet need due to the limited efficacy, safety and compliance profiles of the current products. New entrants will have considerable scope for value capture. The currently used chemotherapy regimens are injectable and so there exists a significant unmet need in terms of compliance. There is also huge potential for products using other types of new technology which promote better compliance and have fewer adverse effects. Drugs entering the market must be developed with a better understanding of the molecular and cellular processes underlying tumor biology and metastatic spread in order to maximize growth potential. The current products for lip and oral cavity cancer have significant side effects, such as neutropenia, thrombocytopenia, anemia, leucopenia and infection. Many patients are left with no choice other than the current products, although they do provide some degree of disease alleviation. Therefore, the global lip and oral cavity cancer therapeutics market is attractive, with significant unmet need in terms of a cure of the underlying cause of the disease. Developing new molecular targeted agents will lead to future blockbusters with the potential to capture a large share of the market. Consequently, there is a huge need for novel drugs with better efficacy, safety and compliance profiles than established products. For Sample Pages, please click or add the below link to your browser: http://globaldata.com/ The weak therapeutic pipeline has with 10 molecules in various Phases of clinical development, meaning that it is unlikely that any of them will be launched in the forecast period. Of these molecules, only two trials are company-sponsored and the rest are being carried out by academic institutions and universities. They are all first-in-class molecules with novel mechanisms of action. The pipeline includes tyrosine kinase inhibitors, immunotherapeutic agents, Histone Deacetylase (HDAC) inhibitors, Toll-Like Receptor 8 (TLR8) agonists, anti-VEGF monoclonal antibodies, anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibodies and mammalian Target of Rapamycin (mTOR) inhibitors. As the majority of these clinical trials are being sponsored by universities they are not expected to significantly impact the future lip and oral cavity cancer therapeutic market. GlobalData, the industry analysis specialist, has released its new report, “Lip and Oral Cavity Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global lip and oral cavity cancer therapeutics market. The report identifies the key trends shaping and driving the global lip and oral cavity cancer therapeutics market. It also provides insights into the current competitive landscape and the emerging players expected to significantly alter the market positions of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global lip and oral cavity cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts For further details, please click or add the below link to your browser: http://globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number